Tangent Medical Technologies

Tangent Medical Technologies specializes in the development of innovative medical devices, particularly focused on enhancing patient care and safety in intravenous therapies. Founded in 2009 and headquartered in Ann Arbor, US, Tangent Medical Technologies operates in the medical device sector. The company was acquired by ICU Medical, Inc. in April 2016.

The firm's activities have primarily concentrated on advancing technology to improve IV therapy solutions. The founder has a history of involvement in the medical industry but no further information is provided about previous ventures or specific individuals. Since its inception, the company has successfully completed 7 deals, raising a total of USD 8. 63 mn through various funding rounds, including the latest round of VENTURE DEBT amounting to USD 5.

00 mn, backed by investors such as GE Capital and Healthcare Financial Services. Tangent Medical Technologies focuses on creating advanced medical devices that improve the safety and efficiency of intravenous therapies. Their core offerings include innovative infusion systems designed to enhance patient care during procedures requiring intravenous delivery. The products are tailored for healthcare providers, aiming to streamline operations and reduce the risk of complications associated with IV therapy.

Tangent Medical Technologies generates revenue through the sale of its medical devices, which are marketed to hospitals and healthcare facilities. The pricing structure is set to reflect the premium quality of their devices, ensuring a reliable stream of income. The company’s flagship product is priced competitively within the market to ensure accessibility to a wide array of healthcare providers. With the recent acquisition by ICU Medical, Tangent Medical Technologies is poised for strategic growth.

Future plans include the launch of new infusion devices targeting specific medical applications, expected to be unveiled in the next fiscal year. The company aims to expand into international markets, primarily focusing on Europe and Asia by 2025. The funding from the latest VENTURE DEBT round will be utilized to accelerate product development, enhance marketing efforts, and facilitate entry into these new markets.